Skip to content

Exploring the potential mechanism of Bifidobacterium breve ProSci-106 adjuvant therapy on Tic disorder

Exploring the potential mechanism of Bifidobacterium breve ProSci-106 adjuvant therapy on Tic disorder

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089438
Enrollment
Unknown
Registered
2024-09-09
Start date
2024-10-01
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tic disorder

Interventions

Probiotics assisted treatment group:Take bifidobacterium breve ProSci-106 and drug (receive standard treatment), once a day, one bag at a time, for a total of 3 months
Placebo group:Take a placebo and drug (receiving standard treatment) once a day, one bag at a time, for 3 months

Sponsors

Inner Mongolia Autonomous Region People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. The legal guardian knows and agrees to participate in the study voluntarily and signs the informed consent; 2. Age 6-14 years old, no gender restrictions; 3. Refer to the American Psychiatric Association's Diagnostic and Statistical Manual of mental disorders (DSM-5) criteria for diagnosis of tic disorder.

Exclusion criteria

Exclusion criteria: 1. Those who do not meet the above inclusion criteria; 2. People who are allergic to probiotics or its ingredients; 3. Patients with primary diseases such as digestive system and immune system, or suffering from other serious diseases; 4. Diet and exercise therapy as recommended by a doctor; 5. Have used antibiotics, probiotics or Biostime within the last month; 6. Exclude involuntary movements that can be explained by other diseases, such as rheumatic chorea, Huntington's disease, hepatolenticular degeneration, hyperactivity disorder, muscle spasms, hysterical attacks, and other extrapyramidal diseases; 7. Participated in other clinical trials within the past month; 8. Subjects who are unwilling to provide personal information and do not wish to be included in the study.

Design outcomes

Primary

MeasureTime frame
Basic information questionnaire;Yale Global Tic Severity Scale-Total Tic Score;

Secondary

MeasureTime frame
Yale Global Tic Severity Scale-Total Score;Gastrointestinal Symptoms Rating Scales;

Countries

China

Contacts

Public ContactYang An

Inner Mongolia Autonomous Region People's Hospital

lxye1720@163.com+86 155 1242 0857

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026